2190 Stock Overview
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2190 from our risk checks.
Zylox-Tonbridge Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.50 |
| 52 Week High | HK$14.66 |
| 52 Week Low | HK$7.20 |
| Beta | 0.42 |
| 1 Month Change | 8.25% |
| 3 Month Change | -1.50% |
| 1 Year Change | -11.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.50% |
Recent News & Updates
Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23
Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Recent updates
Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Shareholder Returns
| 2190 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 10.5% | 4.1% | 3.6% |
| 1Y | -11.5% | -49.9% | -10.1% |
Return vs Industry: 2190 exceeded the Hong Kong Medical Equipment industry which returned -50.6% over the past year.
Return vs Market: 2190 matched the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 2190 volatility | |
|---|---|
| 2190 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2190 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2190's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 765 | Jonathon Zhao | www.zyloxtb.com |
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products.
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamentals Summary
| 2190 fundamental statistics | |
|---|---|
| Market cap | HK$3.44b |
| Earnings (TTM) | -HK$85.11m |
| Revenue (TTM) | HK$570.47m |
6.0x
P/S Ratio-40.4x
P/E RatioIs 2190 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2190 income statement (TTM) | |
|---|---|
| Revenue | CN¥527.75m |
| Cost of Revenue | CN¥142.77m |
| Gross Profit | CN¥384.99m |
| Other Expenses | CN¥463.72m |
| Earnings | -CN¥78.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 72.95% |
| Net Profit Margin | -14.92% |
| Debt/Equity Ratio | 1.6% |
How did 2190 perform over the long term?
See historical performance and comparison